Phase II trial of weekly paclitaxel and carboplatin chemotherapy in patients with advanced transitional cell cancer

European Urology

Volumn 48, Issue 2, 2005, Pages 246-251

  Johannsen, Manfred ^a   Sachs, Markus ^a   Roigas, Jan ^a   Hinke, Axel ^b   Staack, Andrea ^a   Loening, Stefan A ^a   Schnorr, Dietmar ^a   Wille, Andreas H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Wissenschaftlicher Service Pharma (WiSP) Dr Axel Hinke   (Germany)

Author keywords

Carboplatin; Paclitaxel; Transitional cell cancer; Weekly chemotherapy

Indexed keywords

ANTIBIOTIC AGENT; CARBOPLATIN; CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADULT; AGED; ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEVER; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; UROTHELIUM; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AREA UNDER CURVE; CARBOPLATIN; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 21844475424     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.04.035     Document Type: Article

References (26)

1. S.A. Hussain, and N.D. James The systemic treatment of advanced and metastatic bladder cancer Lancet Oncol 4 2003 489 497
2. C.N. Sternberg, A. Yagoda, H.I. Scher, R.C. Watson, N. Geller, and H.W. Herr Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium: efficacy and patterns of response and relapse Cancer 64 1989 2448 2458
3. C.J. Logothetis, F. Dexeus, L. Finn, A. Sella, R.J. Amato, and A.G. Ayala A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumors J Clin Oncol 8 1990 1050 1055
4. P.J. Loehrer Sr., L.H. Einhorn, P.J. Elson, E.D. Crawford, P. Kuebler, and I. Tannock A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study J Clin Oncol 10 1992 1066 1073
5. H. Von der Maase, S.W. Hansen, J.T. Roberts, L. Dogliotti, T. Oliver, and M.J. Moore Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter phase III study J Clin Oncol 18 2000 3068 3077
6. B.J. Roth, R. Dreicer, L.E. Einhorn, D. Neuberg, D.H. Johnson, and J.L. Smith Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group J Clin Oncol 12 1994 2264 2270
7. R. Dreicer, J. Manola, B.J. Roth, M.B. Cohen, A.K. Hatfield, and G. Wilding Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group study J Clin Oncol 18 2000 1058 1061
8. R.S. Go, and A.A. Adjei Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin J Clin Oncol 17 1999 409 422
9. D.J. Vaughn, S.B. Malkowicz, B. Zoltick, R. Mick, P. Ramchandani, and C. Holroyde Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen J Clin Oncol 16 1998 255 260
10. B.G. Redman, D.C. Smith, L. Flaherty, W. Du, and M. Hussain Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma J Clin Oncol 16 1998 1844 1848
11. A. Pycha, M. Grbovic, B. Posch, B. Schnack, A. Haitel, and G. Heinz-Peer Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract Urology 53 1999 510 515
12. C.C. Zielinski, B. Schnack, M. Grbovic, T. Brodowizc, C. Wiltschke, and G. Steger Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial Br J Cancer 78 1998 370 374
13. E.J. Small, D. Lew, B.G. Redman, D.P. Petrylak, N. Hammond, and H.M. Gross Southwest Oncology Group study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point J Clin Oncol 18 2000 2537 2544
14. D. Ukena, M. Leutz, R. Schroder, and G.W. Sybrecht Intensified treatment of stage IV non-small cell lung cancer (NSCLC): weekly chemotherapy with paclitaxel and carboplatin Lung Cancer 18 Suppl 1 1997 34 (abstract 122)
15. T.M. Löffler, W. Freund, and T.U. Hausamen Dose-dense weekly paclitaxel and carboplatin in advanced solid tumors Proc Am Soc Clin Oncol 16 1997 222a
16. A.D. Seidman, C.A. Hudis, J. Albanel, W. Tong, I. Tepler, and V. Currie Dose-dense therapy with weekly 1-hour paclitaxel infusions in the treatment of metastatic breast cancer J Clin Oncol 16 1998 3353 3361
17. D. Belotti, V. Vergani, T. Drudis, P. Borsotti, M.R. Pitelli, and G. Viale The microtubule-affecting drug paclitaxel has antiangiogenic activity Clin Cancer Res 2 1996 1843 1849
18. A.H. Calvert, D.R. Newell, L.A. Grumbell, S. O'Reilly, M. Burnell, and F.E. Boxall Carboplatin dosage: prospective evaluation of a simple formula based on renal function J Clin Oncol 7 1989 1748 1756
19. A.B. Miller, B. Hoogstraten, M. Staquet, and A. Winkler Reporting response of cancer treatment Cancer 47 1981 207 214
20. E.L. Kaplan, and P. Meier Non parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 464
21. D.J. Vaughn, J. Manola, R. Dreicer, W. See, R. Levitt, and G. Wilding Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896). A trial of the Eastern Cooperative Oncology Group Cancer 95 2002 1022 1027
22. R. Dreicer, J. Manola, B.J. Roth, W.A. See, S. Kuross, and M.J. Edelman Phase III trial of methotrexate, vinblastine, doxorubicin and cisplatin versus carboplatin and paclitaxel in patients with advanced carcinoma of the urothelium. A trial of the Eastern Cooperative Oncology Group Cancer 100 2004 1639 1645
23. M. Johannsen, A. Wille, J. Roigas, and D. Schnorr Combination therapy with Taxol and carboplatin in advanced transitional cell cancer Eur Urol 39 Suppl 5 2001 141
24. M. Johannsen, A.H. Wille, J. Roigas, D. Schnorr, and S.A. Loening Phase II trial of paclitaxel and carboplatin in advanced/metastatic transitional cell cancer Eur Urol 2 Suppl 3 2004 177
25. D.M. Friedland, S. Dakhil, C. Hollen, M.A. Gregurich, and L. Asmar A phase II evaluation of weekly paclitaxel plus carboplatin in advanced urothelial cancer Cancer Invest 22 2004 374 382
26. D.F. Bajorin, P.M. Dodd, M. Mazumdar, M. Fazzari, J.A. McCaffrey, and H.I. Scher Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3178